Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (EXCELLENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04304482
Recruitment Status : Recruiting
First Posted : March 11, 2020
Last Update Posted : June 29, 2020
Sponsor:
Collaborators:
Anavex Australia Pty Ltd.
Anavex Germany GmbH
Information provided by (Responsible Party):
Anavex Life Sciences Corp.

Brief Summary:
ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-18 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

Condition or disease Intervention/treatment Phase
Rett Syndrome Drug: ANAVEX2-73 oral liquid Drug: Placebo oral liquid Phase 2 Phase 3

Detailed Description:

This Phase 2/3 efficacy study is designed as a double-blind, randomized, placebo-controlled study.

This is a 12-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 5-18 years of age. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 48-week open label extension.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rett Syndrome

Arm Intervention/treatment
Experimental: ANAVEX2-73 Active
ANAVEX2-73 liquid oral solution
Drug: ANAVEX2-73 oral liquid
Liquid oral solution
Other Name: Blarcamesine

Placebo Comparator: ANAVEX2-73 Placebo
Placebo liquid oral solution
Drug: Placebo oral liquid
Liquid oral solution




Primary Outcome Measures :
  1. RSBQ [ Time Frame: 12 weeks ]
    Change from baseline to End of Treatment (EOT) in the Rett Syndrome Behaviour Questionnaire (RSBQ)

  2. CGI-I [ Time Frame: 12 weeks ]
    Change from baseline to End of Treatment (EOT) in the Clinical Global Impression Improvement Scale (CGI-I) score


Secondary Outcome Measures :
  1. Anxiety, Depression, and Mood Scale (ADAMS) [ Time Frame: 12 weeks ]
    Anxiety, Depression, and Mood Scale (ADAMS)

  2. Motor Behavioral Assessment-7 dynamic pediatric items (MBA-Ped7) [ Time Frame: 12 weeks ]
    Motor Behavioral Assessment-7 dynamic pediatric items (MBA-Ped7)

  3. Children's Sleep Habits Questionnaire (CSHQ) [ Time Frame: 12 weeks ]
    Children's Sleep Habits Questionnaire (CSHQ)

  4. Seizure Frequency via seizure diary [ Time Frame: 12 weeks ]
    Seizure Frequency via seizure diary

  5. Incidence of Adverse Events [ Time Frame: 12 weeks ]
    Incidence of Adverse Events


Other Outcome Measures:
  1. Glutamate Plasma Concentration [ Time Frame: 12 weeks ]
    Glutamate Plasma Concentration

  2. GABA Plasma Concentration [ Time Frame: 12 weeks ]
    GABA Plasma Concentration

  3. Genetic variant SIGMAR1, COMT [ Time Frame: 12 weeks ]
    Genetic variant SIGMAR1, COMT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged ≥ 5 years to <18.
  • Diagnosis of classic RTT, according to 2010 criteria, and a MECP2 mutation.
  • Post-regression stage, defined as ≥ 6 months since last loss of spoken language or motor (fine or gross) skills.
  • Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening.
  • Current pharmacological treatment regimen, including supplements, has been stable for at least 4 weeks.
  • If on AEDs, 1-4 AEDs allowed. Treatment must be stable (drug, dose, interval of administration) for 30 days prior to enrollment.
  • If the subject is already receiving stable non-pharmacologic educational, behavioral, and/or dietary interventions, participation in these programs must have been continuous during the 90 days prior to the screening visit and subjects or their parent/caregiver/LAR will not electively initiate new or modify ongoing interventions for the duration of the study.
  • Ability to keep accurate seizure diaries or have caregiver who can keep accurate seizure diaries.
  • Confirmation from the participant that, if of childbearing potential is not pregnant through urine (or serum) pregnancy testing. Female patients of childbearing potential and at risk for pregnancy must agree to abstinence.
  • Prior to the conduct of study-specific procedures, the subject's parent/caregiver/LAR must provide written informed consent. If applicable, the research team must attempt to obtain consent from both parents.

Exclusion Criteria:

  • Patients who have a progressive medical or neurological condition that in the opinion of the Investigator would interfere with the conduct of the study.
  • Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
  • History or clinically evident neurologic (e.g., head trauma with loss of consciousness) or psychiatric condition that the Investigator deems may interfere with interpretability of data.
  • Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3x upper limit of normal (ULN) as determined during screening.
  • Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.
  • Other clinically significant abnormality on physical, neurological, laboratory, or electrocardiogram (ECG) examination (e.g., long QT) that could compromise the study or be detrimental to the participant.
  • Any known hypersensitivity to any of the excipients contained in the study drug or placebo formulation.
  • Other co-morbid or chronic illness beyond that known to be associated with RTT.
  • Subjects who plan to initiate or change pharmacologic or nonpharmacologic intervention during the course of the study.
  • Subjects taking another investigational drug currently or within the last 30 days.
  • Any other criteria (such as a clinically significant screening blood test result), which in the opinion of the Investigator could interfere with the study conduct or outcome.
  • Subjects on potent CYP 3A4 and CYP2C19 inhibitors and inducers (e.g., oxcarbazepine).
  • Patients with hepatic and renal impairment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04304482


Contacts
Layout table for location contacts
Contact: Walter Kaufmann, MD +1(844)-689-3939 rett@anavex.com

Locations
Layout table for location information
Australia, New South Wales
The Children's Hospital at Westmead Recruiting
Sydney, New South Wales, Australia, 2145
Contact: Carolyn Ellaway, MD         
Principal Investigator: Carolyn Ellaway, MD         
Australia, Queensland
Queensland Children's Hospital Recruiting
Brisbane, Queensland, Australia, 4101
Contact: Honey Heussler, MD         
Principal Investigator: Honey Heussler, MD         
Sponsors and Collaborators
Anavex Life Sciences Corp.
Anavex Australia Pty Ltd.
Anavex Germany GmbH
Layout table for additonal information
Responsible Party: Anavex Life Sciences Corp.
ClinicalTrials.gov Identifier: NCT04304482    
Other Study ID Numbers: ANAVEX2-73-RS-003
First Posted: March 11, 2020    Key Record Dates
Last Update Posted: June 29, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Rett Syndrome
Syndrome
Disease
Pathologic Processes
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System